Article thumbnail

Combination Drug Therapy for Pain following Chronic Spinal Cord Injury

By Aldric Hama and Jacqueline Sagen

Abstract

A number of mechanisms have been elucidated that maintain neuropathic pain due to spinal cord injury (SCI). While target-based therapeutics are being developed based on elucidation of these mechanisms, treatment for neuropathic SCI pain has not been entirely satisfactory due in part to the significant convergence of neurological and inflammatory processes that maintain the neuropathic pain state. Thus, a combination drug treatment strategy, wherein several pain-related mechanism are simultaneously engaged, could be more efficacious than treatment against individual mechanisms alone. Also, by engaging several targets at once, it may be possible to reduce the doses of the individual drugs, thereby minimizing the potential for adverse side effects. Positive preclinical and clinical studies have demonstrated improved efficacy of combination drug treatment over single drug treatment in neuropathic pain of peripheral origin, and perhaps such combinations could be utilized for neuropathic SCI pain. At the same time, there are mechanisms that distinguish SCI from peripheral neuropathic pain, so novel combination therapies will be needed

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3324948
Provided by: PubMed Central

Suggested articles

Citations

  1. (1980). A .A .L a r s o n ,J .L .V a u g h t ,a n dA .E .T a k e m o r i ,“ T h ep o t e n -tiation of spinal analgesia by leucine enkephalin,”
  2. (2003). A .B .M a l m b e r g ,H .G i l b e r t ,R .T .M c C a b e ,a n dA .I . Basbaum, “Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins
  3. (2003). A .H a m a ,J .W .L e e ,a n dJ .S a g e n ,“ D i fferential efficacy of intrathecal NMDA receptor antagonists on inflammatory mechanical and thermal hyperalgesia in rats,”
  4. (2006). A n d e r s o n ,S .O ’ H a r a ,H .C .L a w s o n ,R .D .T r e e d e ,a n d
  5. (1995). A new approach to control central deafferentation pain: spinal intrathecal baclofen,”
  6. (1988). A newandsensitivemethodformeasuringthermalnociception in cutaneous hyperalgesia,”
  7. (2009). A rat is not a monkey is not a human: comment onMogil,”NatureReviewsNeuroscience,vol.10,pp.283–294,
  8. (2007). A role for peripheral afferents in the pathophysiology and treatment of at-level neuropathic pain in spinal cord injury? A case report,”
  9. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster,”
  10. (2007). A.S.Heimann,I.Gomes,C.S.Daleetal.,“Hemopressinisan inverse agonist of CB1 cannabinoid receptors,”
  11. (2002). Actions of intrathecal ω-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat,”
  12. (1971). Activities of narcotic and narcotic-antagonist analgesics following the intraventricular injection of various substances,”
  13. (2009). Additive antinociceptive effects of the selective nav1.8 blocker A803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models,”
  14. (2005). Advances and limitations in the evaluation of analgesic combination therapy,”
  15. (2000). Adverse effects associated with the intrathecal administration of ziconotide,”
  16. (2005). Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome,”
  17. (2007). Alteredantinociceptiveefficacyoftramadol over time in rats with painful peripheral neuropathy,”
  18. (2006). and S.Leone,“Paracetamol:newvistasofanolddrug,”CNSDrug Reviews,
  19. (1992). Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice,”
  20. (2010). Antinociceptive effect ofambroxolinratswithneuropathicspinalcordinjurypain,”
  21. (2009). Antinociceptive effects of the marine snail peptides conantokin-G and conotoxin MVIIA alone and in combination in rat models of pain,”
  22. (2007). Antinociceptive synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat formalin test,”
  23. (1991). Assessment of antinociceptive drug effects in the presence of impaired motor performance,”
  24. (1992). Baclofen reverses the hypersensitivity of dorsal horn wide dynamic range neurons to mechanical stimulation after transient spinal cord ischemia; Implications for a tonic GABAergic inhibitory control of myelinated fiber input,”
  25. (2008). Baclofen-enhanced spinal cord stimulation and intrathecal baclofen alone for neuropathic pain:. long-term outcome of a pilot study,”
  26. (2007). Behavioral characterization and effect of clinical drugs in a rat model of pain following spinal cord compression,”
  27. (2011). Biomarkers for chronic pain and analgesia. Part 1: the need, reality, challenges, and solutions,”
  28. (2002). C a r d e n a s ,C .A .W a r m s ,J .A .T u r n e r ,H .M a r s h a l l ,M . M .B r o o k e ,a n dJ .D .L o e s e r ,“ E fficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial,”
  29. (1994). C h a p l a n ,F .W .B a c h ,J .W .P o g r e l ,J .M .C h u n g ,a n dT
  30. (2007). Calcitonin gene-related peptide immunoreactivity in chronic human spinal cord injury,”
  31. (2011). Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injuryinduced neuropathic pain states,”
  32. (2010). Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain,”
  33. (2009). Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside,”
  34. (2011). Cell based therapy for the management of chronic pain,”KoreanJournalofAnesthesiology,vol.60,no.1,pp.3–7,
  35. (2006). Cell therapy using bone marrow stromal cells in chronic paraplegic rats: systemic or local administration?”
  36. (2005). Changes in electrophysiological properties and sodium channel Na v1.3 expression in thalamic neurons after spinal cord injury,”
  37. (2005). Changes in properties of spinal dorsal horn neurons and their sensitivity to morphine after spinal cord injury in the rat,”
  38. (1997). Chronic central pain after spinal cord injury,”
  39. (2009). Chronic neuropathic pain in spinal cord injury: effi-ciency of deep brain and motor cortex stimulation therapies forneuropathic pain inspinal cord injurypatients,” Annalsof Physical and Rehabilitation Medicine,
  40. (2011). Chronic pain: the basic science,”
  41. (2010). Chronic spontaneous activity generated in the somata of primary nociceptors is associated with pain-related behavior after spinal cord injury,”
  42. (2009). Clinical feasibility for cell therapy using human neuronal cell line to treat neuropathic behavioral hypersensitivity following spinal cord injury in rats,”JournalofRehabilitationResearchandDevelopment,vol.
  43. (1990). Collateral sprouting of the central terminals of cutaneous primary afferent neurons in the rat spinal cord: pattern, morphology, and influence of targets,” J o u r n a lo fC o m p a r a t i v eN e u r o l o g y ,
  44. (2011). Combination drug therapy for chronic pain: a call for more clinical studies,”
  45. (2003). Combination strategies for pain management,”
  46. (2011). Conditioned place preference reveals tonic pain in an animal model of central pain,”
  47. (2010). D.J.KopskyandJ.M.KeppelHesselink,“Anewcombination cream for the treatment of severe neuropathic pain,”
  48. (1994). Decreased GABA immunoreactivity in spinal cord dorsal horn neurons after transient spinal cord ischemia in the rat,”
  49. (1994). Different time-courses of i.v. lidocaine effect onganglionicandspinalunitsinneuropathicrats,”NeuroReport,
  50. (2003). Differential effects of stress on escape and reflex responses to nociceptive thermal stimuli in the rat,”
  51. (2009). Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatorypain,”ChemistryandBiology,vol.16,no.4,pp. 411–420,
  52. (2000). Discovery of “self-synergistic” spinal/supraspinal antinociception produced by acetaminophen (paracetamol),”
  53. (2002). Dorsal root entry zone microcoagulation for spinal cord injury-related central pain: operative intramedullary electrophysiologicalguidanceandclinicaloutcome,”JournalofNeurosurgery,
  54. (2006). Drug discovery in jeopardy,”
  55. (2009). e r e a u ,M .M a l c a n g i o ,a n dG .R .S t r i c h a r t z , “MAP kinase and pain,”
  56. (2004). Effect of age at time of spinal cord injury on behavioral outcomes in rat,”
  57. (2011). Effective treatments for pain in the older patient,”
  58. (1992). Effects of age and size on development of allodynia in a chronic pain model produced by sciatic nerve ligation in rats,”
  59. (2000). Effects of antagonists to highthreshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia,”
  60. (2001). Effects of intrathecal morphine, baclofen, clonidine and R-PIA on the acute allodynia-like behaviours after spinal cord ischaemia in rats,”
  61. (2004). Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain,”
  62. (2009). Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study,”
  63. (1997). Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat,”
  64. (1998). Epidural spinal cord stimulation for the control of spasticity in spinal cord injury patients lacks long-term efficacy and is not cost-effective,”
  65. (2005). Ermund et al., “Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 viafattyacidamidehydrolase-dependentarachidonic acid conjugation in the nervous system,”
  66. (2004). Evaluation and treatment of central pain syndromes,”Neurology,vol.62,no.5,supplement2,pp.S30– S36,
  67. (2000). Evidence-based review of the literature on intrathecal delivery of pain medication,”
  68. (1995). Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain,”
  69. (2008). Functional MRI of the brain detects neuropathic pain in experimental spinal cord injury,”
  70. (2006). G w a k ,H .Y .T a n ,T .S .N a m ,K .S .P a i k ,C .E .H u l s e b o s c h
  71. (1994). GABAA receptor-mediated inhibition of N-methyl-D-aspartate-evoked
  72. (2010). Glial cells and chronic pain,”
  73. (1996). Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection,”
  74. (1992). H a o ,H .A l d s k o g i u s ,A .S e i g e r ,a n dZ . Wiesenfeld-Hallin, “Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury,”
  75. (1992). H e r m a n ,S .C .D ’ L u z a n s k y ,a n dR .I p p o l i t o ,“ I n t r a t h e -cal baclofen suppresses central pain in patients with spinal lesions. A pilot study,”
  76. (2011). https://www.nscisc.uab.edu/public content/pdf/Facts %202011%20Feb%20Final.pdf.
  77. (2005). I.GilronandM.B.Max,“Combinationpharmacotherapyfor neuropathic pain: current evidence and future directions,”
  78. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms,”
  79. (1992). Interaction between opiates andneurotransmitters/neuromodulatorsinspinalanalgesia,”
  80. (1990). Interaction of intrathecal morphine and ST91 on antinociception in the rat: dose-response analysis, antagonism and clearance,”
  81. (2007). Interactions between drugs and occupied receptors,”
  82. (2000). Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury,”
  83. (1996). Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study,”
  84. (2009). Intrathecal therapy: what has changed with the introduction of ziconotide,”
  85. (2009). Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports,”
  86. (2009). Intrathecal ziconotide for neuropathic pain: a review,” Pain Practice,
  87. (2012). Keppel Hesselink, “High doses of topical amitriptyline in neuropathic pain: two cases and literature review,”
  88. Listening” and “talking” to neurons: implications of immune activation for pain control and increasing the effi-cacy of opioids,”
  89. (1993). Longterm survival of veterans with traumatic spinal cord injury,”
  90. (2007). M.Saulino,“Successfulreductionofneuropathicpainassociated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report,”
  91. (2010). Managing pain in the elderly population: pearls and pitfalls,”
  92. (2004). Mechanical allodynia following contusion injury of the rat spinal cord is associated with loss of GABAergic inhibition in the dorsal horn,”
  93. (1995). Mechanical allodynia is more strongly manifested in older rats in an experimental model of peripheral neuropathy,”
  94. (2009). Mechanisms of chronic central neuropathic pain after spinal cord injury,”
  95. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain,” Current MedicalResearchandOpinion,vol.23,no.1,pp.17–24,2007.
  96. (2003). MRI in chronic spinal cord injury patients with and without central pain,”
  97. (2010). Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial,”
  98. (2010). Natural products and ion channel pharmacology,”
  99. (2011). Neuronal hyperexcitability: a substrate for central neuropathic pain after spinal cord injury,”
  100. Nmethyl-aspartate receptor antagonist activity and phencyclidine-like behavioral effects of the pentadecapeptide,
  101. (2009). O’Neal et al., “Blockade of endocannabinoid-degrading enzymes attenuates neuropathicpain,”JournalofPharmacologyandExperimentalTherapeutics,
  102. (1993). Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination,”
  103. (2007). On the lack of evidence that non-human animals possess anything remotely resembling a “theory of mind”,”
  104. (1992). Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ’atypical’ opioid analgesic,”
  105. (2010). Oxycodone combinations for pain relief,”
  106. (2009). P r i c e ,F .C e r v e r o ,M .S .G o l d ,D .L .H a m m o n d ,a n dS
  107. (1998). P.K.Eide,“Pathophysiologicalmechanismsofcentralneuropathic pain after spinal cord injury,”
  108. (1992). Painful neuropathy: altered central processing maintained dynamically by peripheral input,”
  109. (2009). Peripheral NMDA receptors revisited—hope floats,”
  110. (2005). Pharmacological actions of cannabinoids,”
  111. (2004). Pharmacological characterization of the chronic constriction injury model of neuropathic pain,”
  112. (2008). Pharmacological management of neuropathic pain following spinal cord injury,”
  113. (1997). Pharmacology of cannabinoid
  114. (2006). Piomelli,andC.W.Vaughan,“ActionsoftheFAAHinhibitor URB597 in neuropathic and inflammatory chronic pain models,”
  115. (1985). Potentiationofmorphineantinociceptionbymonoaminereuptake inhibitors in the rat spinal cord,”
  116. (2009). Prevention of intrathecal baclofen withdrawal syndrome successful use of a temporary intrathecal catheter,” RegionalAnesthesiaandPainMedicine,vol.34,no.6,pp.600– 602,
  117. (2009). primary somatosensory cortex reorganization following spinal cord injury,”
  118. (2000). R u t k o w s k i ,a n dM .J .C o u s i n s ,“ T h ee fficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury,” Anesthesia and Analgesia,v o l .9 1 ,n o .6 ,p p .
  119. (2007). Reaction to topical capsaicin in spinal cord injury patients with and without central pain,”
  120. (2004). Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia,”
  121. (1989). Recordings of abnormal activity in patients with deafferentiationandcentralpain,”StereotacticandFunctional Neurosurgery,
  122. (2008). Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats,”
  123. (2000). Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats,”
  124. (2009). Restorative effects of stimulating medullary raphe after spinal cord injury,”
  125. (1994). Role of voltagedependent calcium channel subtypes in experimental tactile allodynia,”
  126. (2005). S.M.Tham,J.A.Angus,E.M.Tudor,andC.E.Wright,“Synergistic and additive interactions of the cannabinoid agonist CP55,940 with μ opioid receptor and α2-adrenoceptor agonists in acute pain models in mice,”
  127. (2011). S(+)-ketamine suppresses desensitization of γ-aminobutyric acid type B receptor-mediated signaling by inhibition of the interaction of γ-aminobutyric acid type B receptors with G proteincoupled receptor kinase 4 or 5,” Anesthesiology,
  128. (2007). Segmental hypersensitivity and spinothalamic function in spinal cord injury pain,”
  129. (2005). Segmental organization of spinal reflexes mediating autonomic dysreflexia after spinal cord injury,”
  130. (2003). Sensory function in spinal cord injury patients with and without central pain,”
  131. Simultaneous treatment of intractable pain and spasticity: observations of combined intrathecal baclofenmorphine therapy over a 10-year clinical experience,” EuropeanJournalofPhysicalandRehabilitationMedicine.Inpress.
  132. (1996). Somatosensory findings in patients with spinal cord injury and central dysaesthesia pain,”
  133. (2004). Spinal cord injury pain— mechanisms and treatment,”
  134. Spinal-, brainstem- and cerebrallymediatedresponsesat-andbelow-levelofaspinalcord contusion in rats: evaluation of pain-like behavior,”
  135. (1997). Suppression of neuropathic pain by a naturally-derived peptide with
  136. (1999). Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1-and COX2-inhibitors in nerve-injured rats,”
  137. (2001). Synergistic μ-opioid and 5-HT1A presynaptic inhibition
  138. (2010). Syringomyelia in the cavalier king charles spaniel (CKCS)
  139. (2005). Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and metaanalysis,”
  140. (2000). T s a i ,Y .H .S u n g ,P .J .C h a n g ,F .C .K a n g ,a n dK .S .C h u , “Tramadol relieves thermal hyperalgesia in rats with chronic constriction injury of the sciatic nerve,” Fundamental and Clinical Pharmacology,
  141. (1995). Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram,”
  142. (2000). The alleviation of pain by cell transplantation,”
  143. (2001). The antinociceptive effect of intrathecal administration of epibatidine with clonidine or neostigmine in the formalin test in rats,”
  144. (2000). The antinociceptive effect of tramadol on a model of neuropathic pain
  145. (2005). The effect of antinociceptive drugs tested at different times after nerve injury
  146. (2009). The incidence and management of tolerance in intrathecal baclofen therapy,”
  147. (1999). The induction of pain: an integrative review,”
  148. (2011). The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy,”
  149. (1986). The pharmacohistory of Cannabis sativa,” in Cannabinoids as Therapeutic Agents,
  150. (2006). The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets,”
  151. (1999). The spinal biology in humans and animals of pain states generated by persistent small afferent input,”
  152. (2000). Therapeutic misadventure with paracetamol: fact or fiction?”
  153. (2011). Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain,”CNSandNeurologicalDisorders,vol.10,no.5,pp.589– 609,
  154. (1984). Tolerance to morphine analgesia: decreased multiplicative interaction between spinal and supraspinal sites,”
  155. (2001). Tram` e r ,D .C a r r o l l ,D .J .R e y n o l d s
  156. (1996). Treatment of a chronic allodynialike response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists,”
  157. Trends in new injuries, prevalent cases, and aging with spinal cord injury,” Archives of Physical MedicineandRehabilitation,vol.92,no.3,pp.332–338,2011.
  158. (2003). Types and effectiveness of treatments used by people with chronic pain associated with spinal cord injuries: influence of pain and psychosocial characteristics,”
  159. (2010). Understanding age effects associated with changes in secondary health conditions in a Canadian spinal cord injury cohort,”
  160. (2010). Urban,“Large animal models forpain therapeutic development,” in Translational Pain Research: From Mouse to
  161. (1974). What is it like to be a bat?”
  162. (1989). What is synergy?”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.